In our previous study, using high-throughput screening based on HTS2 (high-throughput sequencing-based high-throughput screening) of over 2,000 compounds, we identified an aurora kinase inhibitor that, when combined with a PD-1 inhibitor, effectively inhibited the growth of TNBC by modulating the JAK1/STAT3 pathway and promoting CD8+ T cell infiltration in the tumor microenvironment (4). The gene discussed is STAT3; the disease is neoplasm.